FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

the aim of this study is to observe the effect of irinotecan-based regimen in patients with advanced colorectal cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: First Affiliated Hospital, Sun Yat-Sen University
• Treatments: Irinotecan; Oxaliplatin

Criteria

Inclusion Criteria:

• histologically confirmed adenocarcinoma in colorectal cancer

• clinical stage Ⅲ or Ⅳa(with potential radical resective metastatic lesions),≥ 12 lymph nodes examined

• no cancer cells were found in ascites

• Eastern Cooperative Oncology Group(ECOG) performance status of 0-2

• male or female, between 18 and 75 years old

• adequate hematologic, hepatic and renal functions

• without severe heart disease in the last 6 months before enrolled. If with hypertension or coronary artery disease, it can be controlled

• not enrolled into others clinical trial during this study

• all patients should sign the informed consent

Exclusion Criteria:

• can not be tolerated operation

• receiving others therapy(including Traditional Chinese herbs)for this disease, can not obey the investigator during the study

• can not be tolerated the adverse effect of drugs in these regimens

• major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from major surgery

• metastatic disease more than one organ

• pregnant or lactating women